Diabetic Neuropathic Pain Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1500

16:07 EDT 12 Aug 2017 | BioPortfolio Reports

DelveInsight's, Diabetic Neuropathic Pain Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Diabetic Neuropathic Pain. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Diabetic Neuropathic Pain. This report provides information on the therapeutic development for Diabetic Neuropathic Pain, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, preclinical as well as discovery products. The report further contains details on dormant products and discontinued products. Therapeutic assessment of all the active products by route of administration and molecule type is also covered in this report.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Astellas Pharma Inc.; BioDelivery Sciences International Inc.; Boehringer Ingelheim GmbH; Daiichi Sankyo Company Limited; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Hydra Biosciences Inc.; Immune Pharmaceuticals Inc.; Laboratorios Del Dr. Esteve S.A.; Lohocla Research Corporation; Mertiva AB; Novaremed; PeriphaGen Inc.; Pharmaleads; Prismic Pharmaceuticals Inc.; Relmada Therapeutics Inc.; Sphaera Pharma Pvt. Ltd.; Theravasc Inc.; NeuromaxBionevia; ViroMed Co. Ltd.; VM BioPharma; Mitsubishi Tanabe Pharma Corporation; Grifols Biologicals Inc.; Bayer; Pfizer
Diabetic Neuropathic Pain Pipeline Drugs
Diabetic Neuropathic Pain Pipeline Assessment
Diabetic Neuropathic Pain Pipeline Analysis
Diabetic Neuropathic Pain Drugs under Development
Diabetic Neuropathic Pain Discovery drugs
Diabetic Neuropathic Pain Preclinical drugs
Diabetic Neuropathic Pain Phase I drugs
Diabetic Neuropathic Pain Phase II drugs
Diabetic Neuropathic Pain Phase III Pipeline Drugs Assessment
Diabetic Neuropathic Pain Preregistration drugs
Diabetic Neuropathic Pain Molecules in pipeline

Original Article: Diabetic Neuropathic Pain Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1500


More From BioPortfolio on "Diabetic Neuropathic Pain Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1500"

Quick Search

Relevant Topics

Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...

Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...

Pain Disorder
Pain is a feeling (sharp or dull) triggered in the nervous system which can be transient or constant. Pain can be specific to one area of the body eg back, abdomen or chest or more general all over the body eg muscles ache from the flu. Without pain ...